Biologics Patent Enforcement: Regeneron Patents Block Biosimilar Entry for EYLEA

Retrieved on: 2025-01-29 20:29:52

Tags for this article:

Click the tags to see associated articles and topics

Biologics Patent Enforcement: Regeneron Patents Block Biosimilar Entry for EYLEA. View article details on hiswai:

Excerpt

The BPCIA provides an abbreviated pathway for FDA approval of biosimilar products while balancing innovator patent rights through complex litigation ...

Article found on: patentlyo.com

View Original Article